Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23rd 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population

October 23rd 2023

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

October 13th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib in combination with obinutuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.

FDA Grants Priority Review to Odronextamab in Relapsed/Refractory Follicular Lymphoma or DLBCL

September 29th 2023

The FDA has granted priority review to the biologics license application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma who have progressed after at least 2 prior systemic therapies.

Deeper Understanding of immune System Could Advance Treatment Options in Lymphoma

September 26th 2023

Stephen M. Ansell, MD, PhD, discusses the successes and challenges of utilizing immune therapy across the landscape of hematologic malignancies, the importance of increasing the understanding of how the immune system functions in patients with lymphoma, and ongoing research of immune therapy for this patient population.

Epcoritamab Wins European and Japanese Approval for Select Types of R/R LBCL

September 25th 2023

Epcoritamab-bysp has been approved by the European Commission and Japan's Ministry of Health, Labour, and Welfare for the treatment of select patients with relapsed/refractory large B-cell lymphoma.

Novel Combinations Seek to Build Off Lenalidomide/Rituximab Backbone in Indolent Lymphoma

September 25th 2023

Paolo Strati, MD, discusses novel combinations for the treatment of indolent B-cell lymphoma, emphasizes the primary goal of improving the efficacy of immunotherapy and providing patients with chemotherapy-free treatment options, and highlights ongoing trials are investigating various approaches to enhance the activity of lenalidomide/rituximab

SLS009 Demonstrates Activity, Safety in Relapsed/Refractory Lymphoma

September 21st 2023

Treatment with SLS009 generated clinical activity and was safe in patients with relapsed/refractory lymphomas.

Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FL

September 19th 2023

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

FDA Grants Fast Track Designation to KT-333 in R/R CTCL and PTCL

September 18th 2023

The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma and relapsed/refractory peripheral T-cell lymphoma.

Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma

September 15th 2023

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Dr. Ansell on the Development of Potential Immune-Harnessing Therapeutics in Lymphoma

September 14th 2023

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Golidocitinib NDA Under NMPA Review for Relapsed/Refractory PTCL

September 14th 2023

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of golidocitinib for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.

Dr Westin on the Updated Treatment Paradigm in Second-Line LBCL

September 13th 2023

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Considerations for CAR T-Cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

September 13th 2023

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 8th 2023

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Fixed-Duration Data Foreshadow Earlier Use of Loncastuximab Tesirine in Relapsed/Refractory DLBCL

September 8th 2023

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma.

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL

September 7th 2023

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Dr Burke on Treatment Paradigm Shifts in Relapsed DLBCL

September 7th 2023

John Burke, MD, discusses the evolution of the diffuse large B-cell lymphoma treatment paradigm.